NASDAQ: TBIOTelesis Bio Inc Stock
$4.50+0.15 (+3.45%)
Updated May 17, 2024
TBIO Price
$4.50
Fair Value Price
N/A
Market Cap
$7.57M
52 Week Low
$3.96
52 Week High
$43.02
P/E
-0.16x
P/B
-0.92x
P/S
0.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.63M
Earnings
-$45.24M
Gross Margin
60.4%
Operating Margin
-171.1%
Profit Margin
-191.3%
Debt to Equity
-5.06
Operating Cash Flow
-$27M
Beta
1.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TBIO Overview
Codex DNA, Inc. manufactures and sells synthetic biology instruments, reagents, associated products, and provides related services to pharmaceutical and academic laboratories worldwide. Its solutions and products include BioXp, BioXp portal, BioXp kits, Cloud-based scripts, Benchtop reagents, and Biofoundry Services. Known as SGI-DNA, Inc.until 2020/03, Codex DNA was incorporated in 2011 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TBIO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TBIO due diligence checks available for Premium users.
Be the first to know about important TBIO news, forecast changes, insider trades & much more!
TBIO News
Valuation
TBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
30.6x
Market
30.97x
TBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.92x
Industry
4x
TBIO's financial health
Profit margin
Revenue
$3.4M
Net Income
-$8.6M
Profit Margin
-268.1%
TBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.3M
Liabilities
$41.7M
Debt to equity
-5.06
TBIO's short-term assets ($23.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TBIO's long-term liabilities ($35.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$12.2M
Financing
-$27.0k
TBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TBIO vs Medical Device Stocks
Telesis Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.